Lupin flags higher US drug prices and shortage risks from proposed generic-drug tariffs
Lupin’s global CFO says shifting generic-drug manufacturing to the US will require assured volumes, viable pricing and subsidies. The company warns proposed tariffs could lift medicine prices or create shortages, while pursuing India’s GLP-1 opportunity with generic semaglutide and Bofanglutide plans.
What happened
Lupin says proposed US generic-drug tariffs could raise medicine prices or cause shortages, while US manufacturing needs volume, pricing and subsidy guarantees.
Key facts
- 100% US tariff on generic drugs from August 2028
- 200% US tariff on generic drugs from August 2029
- Two-year tariff-free period from August 1, 2026
- Logistics costs 14-15% higher for domestic manufacturers
- Around 50% of Investigational New Drug filings come from China
Why this matters
Prioritize US manufacturing partnerships or acquisitions only where long-term purchase commitments, viable reimbursement pricing and public subsidies de-risk the economics.
What to watch
- Final tariff scope, rate, start date, and whether finished doses, APIs, excipients, or specific countries are covered.
- FDA drug-shortage-list changes and any explicit exemptions for essential or shortage medicines.
- US government commitments on manufacturing tax credits, guaranteed procurement volumes, BARDA/strategic-stockpile contracts, or state-level incentive packages.
- Generic-drug price increases or supply-allocation notices from major wholesalers and pharmacy purchasing groups.
- Announcements of US manufacturing, packaging, or CDMO partnerships by Lupin, Sun Pharma, Dr. Reddy's, Aurobindo, and Cipla.
- FDA inspection cadence and approval timelines for India-based plants versus proposed US-based capacity.
- Progress of Indian GLP-1 launches, semaglutide patent timing, and Bofanglutide clinical/regulatory milestones.
- Indian generic-drug manufacturers will seek US tariff exemptions for essential medicines, shortage-prone products, and existing long-term supply contracts.
- Lupin and peers will evaluate US finishing, packaging, contract manufacturing, and joint-venture options before committing to full API relocation.
- Wholesalers, pharmacy chains, and hospital buyers will increase dual sourcing, negotiate tariff-sharing clauses, and build inventories for critical generic SKUs.
- Manufacturers will prioritize higher-margin, complex generics and GLP-1 opportunities, while reassessing low-price commodity products that cannot absorb tariff costs.
- US policymakers may pair tariff proposals with domestic-manufacturing subsidies, purchase-volume guarantees, accelerated approvals, or stockpile contracts.